Skip to main content

Peer Review reports

From: Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials

Original Submission
26 Mar 2021 Submitted Original manuscript
3 Apr 2021 Author responded Author comments - Eva Maria Gamper
Resubmission - Version 2
3 Apr 2021 Submitted Manuscript version 2
21 Apr 2021 Author responded Author comments - Eva Maria Gamper
Resubmission - Version 3
21 Apr 2021 Submitted Manuscript version 3
5 May 2021 Reviewed Reviewer Report
15 May 2021 Reviewed Reviewer Report
27 May 2021 Author responded Author comments - Eva Maria Gamper
Resubmission - Version 4
27 May 2021 Submitted Manuscript version 4
16 Jun 2021 Author responded Author comments - Eva Maria Gamper
Resubmission - Version 5
16 Jun 2021 Submitted Manuscript version 5
7 Jul 2021 Author responded Author comments - Eva Maria Gamper
Resubmission - Version 6
7 Jul 2021 Submitted Manuscript version 6
Publishing
16 Jul 2021 Editorially accepted
7 Oct 2021 Article published 10.1186/s12885-021-08609-7

You can find further information about peer review here.

Back to article page